OPKO Health, Inc. (OPK) is a multinational biopharmaceutical and diagnostics company, engaging in discovering, developing, and commercializing a variety of health care technologies. The company operates in two primary segments, namely pharmaceuticals and diagnostics.
Established in 1991 and headquartered in Miami, Florida, OPKO Health is dedicated to improving patient care and quality of life through innovative medicines and diagnostics. The company prides itself on exploring novel technologies and therapies to tackle the most challenging health issues worldwide. OPKO employs a diversified business model to achieve its core objectives, integrating an array of medical disciplines such as genetics, biochemistry, molecular biology, and pharmacology.
In its pharmaceutical segment, OPKO Health is actively involved in the research and development of several solutions for multiple diseases, specifically related to cardiology, nephrology, and neurology. This segment is known for its development of unique drugs in areas such as human growth hormone deficiency and chronic kidney disease. Furthermore, OPK offers Rayaldee for the treatment of secondary hyperparathyroidism in adults with chronic kidney disease and vitamin D insufficiency.
The diagnostics segment, on the other hand, is driven by BioReference Laboratories, one of the largest full-service laboratories in the US, which provides a broad testing portfolio to physicians, clinics, hospitals, and government entities. It also includes GeneDx — a world-renowned genetics and genomics laboratory — which specializes in diagnosing rare and ultra-rare disorders. Moreover, the company’s diagnostic capabilities extend to innovative solutions like the 4Kscore® test used to assess a male patient’s risk for aggressive prostate cancer.
Under the leadership of Dr. Phillip Frost, CEO, Chairman of the Board, OPKO Health, Inc. has experienced robust growth. The company (NASDAQ: OPK) has been publicly traded since 2007, and it has remained committed to delivering innovative healthcare solutions that not only address today's medical challenges, but also anticipate and prepare for future health needs.
OPKO Health, Inc. maintains a global presence, operating in more than 30 countries across North and South America, Europe, the Middle East, and Asia. To ensure continued innovation and growth, the company engages in strategic alliances, acquisitions, and investments in complementary businesses and technologies. These ventures significantly contribute to the company's goal of enhancing global health by continually pushing the boundaries of medical science and technology.